| Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer (NCT03825289) | University of Utah | 2019-01-30 |
| VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer (NCT03373188) | Emory University | 2017-12-15 |
| Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer (NCT03154190) | Stanford University | 2017-08-08 |
| Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer (NCT01959672) | University of Nebraska | 2013-09-06 |
| Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer (NCT01534637) | Wake Forest University Health Sciences | 2006-08-01 |
| Eribulin Mesylate as Second-Line Therapy for Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer Patients (NCT00383760) | National Cancer Institute (NCI) | 2006-08-01 |
| Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery (NCT00114179) | National Cancer Institute (NCI) | 2005-01-01 |
| Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer (NCT00096070) | National Cancer Institute (NCI) | 2004-12-01 |
| Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer (NCT00091026) | National Cancer Institute (NCI) | 2004-07-01 |
| Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00088894) | National Cancer Institute (NCI) | 2004-06-01 |
| EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer (NCT00087191) | National Cancer Institute (NCI) | 2004-05-01 |
| CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT00075647) | National Cancer Institute (NCI) | 2003-12-01 |
| Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer (NCT00063947) | National Cancer Institute (NCI) | 2003-05-01 |
| Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer (NCT00047307) | National Cancer Institute (NCI) | 2002-08-01 |
| UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer (NCT00039403) | National Cancer Institute (NCI) | 2002-04-01 |
| Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (NCT00030498) | National Cancer Institute (NCI) | 2001-12-01 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer (NCT00028496) | National Cancer Institute (NCI) | 2001-11-01 |
| Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer (NCT00019006) | National Cancer Institute (NCI) | 1995-03-01 |
| Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer (NCT00253526) | National Cancer Institute (NCI) | |